Qiagen NV

Latest Results (13.11.2025):

Qiagen NV reported strong Q3 2025 performance with net sales of $533 million, reflecting a 6% growth at actual rates, alongside a diluted EPS of $0.60 and an adjusted diluted EPS of $0.61 – surpassing the company’s outlook. The results were underpinned by healthy core sales growth across key areas such as QIAstat-Dx and QuantiFERON, as well as a solid adjusted operating income margin of 29.6%. The company also highlighted its robust operating cash flow of $165 million and strategic moves including the acquisition of Parse Biosciences and a $500 million synthetic share repurchase approval, all while reaffirming its full-year 2025 outlook for continued growth.

Strong Financial Performance

In Q3 2025, Qiagen NV delivered net sales of $533 million with a 6% actual rate increase and achieved a diluted EPS of $0.60, with adjusted diluted EPS reaching $0.61, exceeding the company’s outlook target.

Impressive Operational Efficiency

The company maintained a robust adjusted operating income margin of 29.6%, reflecting effective cost management and a strong operational structure despite external challenges such as currency movements and tariffs.

Organic and Product Segment Growth

Core sales grew by 6% CER, led by robust performances in key product areas: QIAstat-Dx and QuantiFERON each grew 11% CER, while Sample technologies increased by 3% CER, indicating broad-based organic momentum.

Solid Cash Flow and Shareholder Returns

Qiagen NV reported ongoing strong operating cash flow of $165 million in Q3 2025 and approved a $500 million synthetic share repurchase, intended for early January 2026, contributing to its goal of returning over $1 billion to shareholders ahead of schedule.

Strategic Expansion and Future Outlook

The acquisition of Parse Biosciences marks a strategic expansion into the fast-growing single-cell market, while the firm also reaffirmed its full-year 2025 outlook with net sales expected to grow by about 4-5% CER and raised its adjusted diluted EPS target to approximately $2.38 CER. Additionally, a planned CEO transition was noted for lasting leadership continuity.